PetVivo Holdings Files Q3 2025 10-Q

TL;DR

PETV filed its Q3 10-Q. Check financials.

AI Summary

PetVivo Holdings, Inc. filed its 10-Q for the period ending December 31, 2024. The company reported its financial results for the third quarter and the first nine months of its fiscal year. Specific financial figures such as revenue, net income/loss, and cash flow are detailed within the report, though not explicitly stated in this header.

Why It Matters

This filing provides investors with an update on PetVivo Holdings' financial performance and operational status for the third quarter of fiscal year 2025.

Risk Assessment

Risk Level: medium — As a publicly traded company filing a 10-Q, there are inherent risks associated with its financial performance and market position.

Key Numbers

• P84M — Total Assets (Reported as of December 31, 2024)
• P63M — Total Liabilities (Reported as of December 31, 2024)
• P3Y — Total Equity (Reported as of December 31, 2024)

Key Players & Entities

• PetVivo Holdings, Inc. (company) — Filer of the 10-Q
• 2024-12-31 (date) — End of the reporting period
• 2025-02-14 (date) — Filing date
• 5251 Edina Industrial Blvd, Edina, MN 55439 (address) — Company's business and mailing address

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 PETV The Nasdaq Stock Market LLC

Filing Documents

• form10-q.htm (10-Q) — 1134KB
• ex31-1.htm (EX-31.1) — 18KB
• ex31-2.htm (EX-31.2) — 18KB
• ex32-1.htm (EX-32.1) — 9KB
• ex32-2.htm (EX-32.2) — 9KB
• 0001493152-25-006783.txt ( ) — 6510KB
• petv-20241231.xsd (EX-101.SCH) — 47KB
• petv-20241231_cal.xml (EX-101.CAL) — 61KB
• petv-20241231_def.xml (EX-101.DEF) — 234KB
• petv-20241231_lab.xml (EX-101.LAB) — 412KB
• petv-20241231_pre.xml (EX-101.PRE) — 323KB
• form10-q_htm.xml (XML) — 1035KB

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION 4 Item 1.

Financial Statements

Financial Statements 4 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 28 Item 3. Qualitative and Quantitative Disclosures About Market Risk 34 Item 4.

Controls and Procedures

Controls and Procedures 34

OTHER INFORMATION

PART II. OTHER INFORMATION 34 Item 1.

Legal Proceedings

Legal Proceedings 34 Item 1A.

Risk Factors

Risk Factors 34 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 35 Item 3. Defaults Upon Senior Securities 35 Item 4. Mine Safety Disclosure 35 Item 5. Other information 35 Item 6. Exhibits 36

SIGNATURES

SIGNATURES 37 2 Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995 Information included in this Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended ("Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended ("Exchange Act"). This information may involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of PetVivo Holdings, Inc. (the "Company"), to be materially different from future results, performance, or achievements expressed or implied by any forward-looking statements. Forward-looking statements, which involve assumptions and describe future plans, strategies, and expectations of the Company, are generally identifiable by use of the words "may," "will," "should," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. These forward-looking statements are based on assumptions that may be incorrect, and there can be no assurance that the projections included in these forward-looking statements will come to pass. Actual results of the Company could differ materially from those expressed or implied in the forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, those discussed in "Risk Factors" included in documents we file from time to time with the U.S. Securities and Exchange Commission (the "SEC'), including our Annual Report on Form 10-K for our fiscal year ended March 31, 2024, ("2023 10-K Report") and risks described in other SEC filings. Except as required by applicable laws, the Company has no obligation to update publicly any forward-looking statements for any reason, even if new information becomes available or other events occur in the future. 3 PART I. ITEM 1. FINANCIAL STAT

Notes to Consolidated Financial Statements

Notes to Consolidated Financial Statements December 31, 2024 (Unaudited) NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION (A) Organization and Description The Company is in the business of licensing and commercializing our proprietary medical devices and biomaterials for the treatment and/or management of afflictions and diseases in animals, initially for dogs and horses. The Company began commercialization of its lead product Spryng with OsteoCushion Technology, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions such as osteoarthritis in dogs and horses in September 2021. The Company has a pipeline of additional products for the treatment of animals in various stages of development. A portfolio of nineteen patents protects the Company's biomaterials, products, production processes and methods of use. The Company's operations are conducted from its headquarter facilities in suburban Minneapolis, Minnesota. (B) Basis of Presentation PetVivo Holdings, Inc. (the "Company") was incorporated in Nevada under its former name in 2009 and entered its current business in 2014 through a stock exchange reverse merger with PetVivo, Inc., a Minnesota corporation. This merger resulted in PetVivo, Inc. becoming a wholly owned subsidiary of the Company. In April 2017, the Company acquired another Minnesota corporation, Gel-Del Technologies, Inc., through a statutory merger, which is also a wholly-owned subsidiary of the Company. The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States ("GAAP") for interim financial reporting and pursuant to the rules and regulations of the SEC. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments (including those which are normal and recu

financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended March 31, 2024

financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended March 31, 2024. (C) Principles of Consolidation The accompanying consolidated financial statements include the accounts of the Company and its two wholly owned Minnesota corporations, Gel-Del Technologies, Inc. and PetVivo, Inc. All intercompany accounts have been eliminated during consolidation. (D) Use of Estimates In preparing financial statements in conformity with generally accepted accounting principles, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include collectability of accounts receivable, inventory obsolescence, estimated useful lives and potential impairment of property and equipment and intangibles, estimate of fair value of share-based payments, distributor rebate payable, provision for product returns, right of use lease assets and liabilities and valuation of deferred tax assets. 9 (E) Cash and Cash Equivalents The Company considers all highly-liquid, temporary cash investments with an original maturity of three months or less to be cash equivalents. The Company had no cash equivalents at December 31, 2024 and March 31, 2024. (F) Concentration Risk The Company maintains its cash with various financial institutions, which at times may exceed federally insured limits. At December 31, 2024, and March 31, 2024 the Company did not have cash balances in excess of the federally insured limits. (G) Accounts Receivable Accounts receivable consist primarily of amounts due from distributors (see revenue recognition). Accounts receivable is recorded based on management's assessment of the expected consideration to be received, based on a detailed revie

View Full Filing

View this 10-Q filing on SEC EDGAR